Overview

Study of Nivolumab in Combination With Ipilimumab in Chinese Subjects With Previously Treated Advanced or Recurrent Solid Tumors

Status:
Recruiting

Trial end date:
2024-11-12

Target enrollment:

Participant gender:

Summary

A Study to Evaluate Safety and Effectiveness of Nivolumab in Combination With Ipilimumab in Chinese Patients With Previously Treated Late-Stage Cancer

Phase:

Phase 1

Details

Lead Sponsor:

Bristol-Myers Squibb

Treatments:

Antibodies, Monoclonal
Ipilimumab
Nivolumab